International Association for Cannabinoid Medicines
The International Association for Cannabinoid Medicines (IACM), formerly known as the "International Association for Cannabis as a Medicine", is a non-profit scientific society founded in Cologne in 2000 and dedicated to the advancement of knowledge of cannabis and cannabinoid medicines among medical professionals. IACM is one of the few global non-profit medical societies or associations related to cannabis and Cannabinoids, along with the Society of Cannabis Clinicians and the International Cannabinoid Research Society. History. The IACM was founded in 2000 as the "International Association for Cannabis as a Medicine" by a group of  members of the German Association for Cannabis as Medicine ("Arbeitsgemeinschaft Cannabis als Medizin"). The chairmanship of the board of IACM has been held by different researchers along the years: Work. The IACM has been known for holding updated lists of medical effects, possible clinical indications of cannabis products and side effects, which are seen by some as a reference. In June 2018, IACM took part in the open session of the World Health Organization's Expert Committee on Drug Dependence meeting related to medical cannabis and joined an official civil society statement in December 2020 to the United Nations Commission  on Narcotic Drugs which resulted in the change of international scheduling of cannabis. During the COVID-19 pandemic, the Board of IACM issued a statement saying that "there is no evidence that individual cannabinoids [...] or cannabis preparations protect against infection with the SARS-CoV2 virus or could be used to treat COVID-19" while mentioning that the IACM-Bulletin reported on several occasions on laboratory studies suggesting that cannabinoids may have antiviral or antibacterial effects. Publications. IACM publishes a bi-weekly Bulletin in various languages. Between 2001 and 2004, IACM edited the scholarly "Journal of Cannabis Therapeutics" published by Haworth Press. Since  2019, IACM has been one of the official societies of the journal "Cannabis and Cannabis Research" published by Mary Ann Liebert"." IACM only conducted one own clinical study: a cross-sectional survey completed by 953 participants from 31 countries about their methods of administration of medical cannabis. Conferences. Starting in 2001 in Berlin, the IACM has been holding biannual scientific conferences in Cologne in 2003, Leiden in 2015, Cologne in 2007 and 2009, Bonn in 2011, Cologne in 2013, Sestri Levante in 2015, Cologne in 2017, Berlin in 2019, and the 20th anniversary conference of 2020 planned to be held  in Mexico City took place online due to the COVID-19 pandemic. The association gives the "IACM Awards" to "outstanding clinicians and scientists for their major contributions to cannabinoid research and/or to the re-introduction of cannabis into modern medicine." In 2014, IACM former chairman and board member Prof. Raphael Mechoulam was given a special award. Patient Council. In 2022, IACM launched the IACM Patient Council, whose purpose is to bring together groups of medical patient using cannabis and cannabinoids, in order for them to share their experience. The statutory articles of IACM describe the Patient Council as follows:The IACM  Patient Council consists of patients, caregivers of patients and nominees from IACM Partner Organisations, who want to support the work of the IACM. The number of members may be limited by the Board of Directors. Members counsel the board with regard to patient issues. Members of the IACM Patient Council may organize their own activities within the framework of the IACM and its conferences.